Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Finance Watch: Ascletis First Biotech To List Under New Hong Kong Rules, BeiGene Joins In

Executive Summary

Ascletis was the first with a new listing under new Hong Kong rules, but BeiGene also sold shares on the HKEX; the companies raised more than $1bn combined. Also, TherapeuticsMD sold stock in the US to commercialize Imvexxy, Curon raised the latest $150m VC mega-round, and NewLink cut jobs in R&D refocus.


Related Content

Deal Watch: BioCryst Shareholder Dissent Scuttles Planned Merger With Idera
Deal Watch: Amazon Moves Into Rx Services With Acquisition Of PillPack
As A New Rival Approaches, PARP Makers Look To Carve Out Their Niche
Pipeline Watch: Phase III Progress With Semaglutide, Tecentriq And Epidaza
BeiGene Bags $750m, Sees China Reforms Creating New Opportunities
Pipeline Watch: Phase III Progress With Esaxerenone, Lusutrombopag
Celgene Eyes IO Growth With BeiGene China Pact
China Direct-Acting HCV Drug Race Rapidly Gathering Pace
Ascletis Eyes Launch Of China’s First Oral HCV Drug, Possible IPO
BeiGene In Deal-Making Mood Following US IPO


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts